Celularity to serve as the exclusive partner for the finish manufacturing of Vesalius’s Peptual peptide APIs, supporting Vesalius’s expansion into pharmaceutical ingredient supply Collaboration advances Celularity’s regenerative longevity vision and creates an opportunity to expand revenue through its U.S . manufacturing infrastructure and technical expertise FLORHAM PARK, N.J. & SCOTTSDALE, Ariz. --(BUSINESS WIRE)-- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, and Vesalius Longevity Labs Inc. (“Vesalius”), a leading, global peptide and longevity brand, today announced that they have entered into an exclusive manufacturing agreement to establish a dedicated, first-of-its-kind, U.S . final stage API manufacturing and supply platform for Vesalius’s Peptual-branded active pharmaceutical ingredients (“APIs”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029804397/en/ The collaboration expands Celularity’s regenerative longevity platform by applying Celularity’s U.S .-based manufacturing infrastructure and technical capabilities to support the development of Vesalius's Peptual ® -branded peptide APIs at its Florham Park, New Jersey facility. It builds on Celularity’s experience manufacturing complex biologics to current good manufacturing practice (“cGMP”) standards, extending those capabilities into peptide API manufacturing while supporting its broader vision of advancing regenerative longevity. Under the collaboration, Celularity will perform downstream purification, processing, analytical testing and manufacturing activities using supplier-provided bulk peptide material. The work is intended to establish peptide-specific manufacturing processes that satisfy cGMP requirements, supported by defined product specifications, documented sourcing and lot-level traceability. The collaboration is intended to position the parties to respond to potential regulatory developments affecting peptide compounding. If and when the U.S. Food and Drug Administration (“FDA”), following its consideration of recommendations from the Pharmacy Compounding Advisory Committee (“PCAC”), adds covered peptide substances and forms to its list of bulk drug substances that may be used in compounding under federal law, the parties intend to supply eligible Peptual-branded APIs to appropriately licensed U.S . compounding pharmacies. The collaboration will not involve manufacturing GLP-1 receptor agonists or other weight-loss peptides, as these products are excluded from Vesalius’s business model. “Peptides represent an important category of products which can work to augment the clinical utility of conventional therapeutics, and we believe can complement our regenerative cellular products,” said Robert J. Hariri , M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity . “We have invested in a purpose-built U.S . facility and assembled a team with experience manufacturing complex medicines. As such, our collaboration with Vesalius represents an important business opportunity for Celularity and a practical extension of our regenerative longevity strategy.” The collaboration comes amid regulatory scrutiny of the quality and provenance of imported pharmaceutical ingredients. The FDA has highlighted concerns about peptide APIs from unverified foreign sources and has separately urged compounding pharmacies to verify their ingredient suppliers, understand the testing performed and identify the original API manufacturer. Celularity and Vesalius believe these concerns create an imperative for a domestic manufacturing platform to strengthen pharmaceutical supply-chain resilience and U.S . national health preparedness. By bringing key downstream manufacturing activities onshore, the collaboration is intended to establish a more transparent path from bulk peptide material through final API release. “We selected Celularity because its facility, technical personnel and experience manufacturing complex biological products provide a strong foundation for our peptide API sourcing plans,” said Pradeep Albert , CEO of Vesalius. “Celularity’s capabilities complement our Peptual platform and commercialization strategy. Together, we aim to establish a U.S . domestic supply platform supported by documented manufacturing processes, defined quality specifications and traceability from supplier inputs through final API release.” For patients and prescribing physicians, uncertainty about an ingredient’s origin, identity and purity raises practical questions about what is being supplied and the evidence supporting its quality. Meaningful transparency requires documentation connecting each lot to its original source, the manufacturing controls applied and the testing supporting its release. The parties intend to build that accountability into the planned platform, supporting informed sourcing decisions by pharmacies and pr